TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Tissue inhibitor of metalloproteinases-1 (TIMP-1) is one of four inhibitors of the matrix metalloproteinases, which are capable of degrading most components of the extracellular matrix. However, in recent years, TIMP-1 has been recognised as a multifunctional protein, playing a complex role in cancer. In this regard, several studies have demonstrated an antiapoptotic effect of TIMP-1 in a number of different cell types. Since chemotherapy works by inducing apoptosis in cancer cells, we raised the hypothesis that TIMP-1 promotes resistance against chemotherapeutic drugs. In order to investigate this hypothesis, we have established TIMP-1 gene-deficient and TIMP-1 wild-type fibrosarcoma cells from mouse lung tissue. We have characterised these cells with regard to TIMP-1 genotype, TIMP-1 expression, malignant transformation and sensitivity to chemotherapy-induced apoptosis. We show that TIMP-1 gene deficiency increases the response to chemotherapy considerably, confirming that TIMP-1 protects the cells from apoptosis. This is to our knowledge the first study investigating TIMP-1 and chemotherapy-induced apoptosis employing a powerful model system comprising TIMP-1 gene-deficient cells and their genetically identical wild-type controls. For future studies, this cell system can be used to uncover the mechanisms and signalling pathways involved in the TIMP-1-mediated inhibition of apoptosis as well as to investigate the possibility of using TIMP-1 inhibitors to optimise the effect of conventional chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing TP53 status in human tumours to evaluate clinical outcome
Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659
Murphy, F. R., Issa, R., Zhou, X., Ratnarajah, S., Arthur, M. J. P., Benyon, C., Iredale, J. P., & Nagase, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111490200 · Cited by 432 · cited 3×
“…increased sensitivity to chemotherapeutic drugs TIMP-1 has been demonstrated to inhibit apoptosis induced by various stimuli in several different types of cells (Guedez et al, 1998; Li et al, 1999; Murphy et al, 2002; Lee et al, 2003; Liu et al, 2003, 2005; Boulday et al, 2004; Murphy et al, 2004).”
Background
Cited by
Progress in matrix metalloproteinase research
MURPHY, G., & NAGASE, H. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.05.002 · Cited by 759
Kolenda, J., Jensen, S. S., Aaberg-Jessen, C., Christensen, K., Andersen, C., Brünner, N., & Kristensen, B. W. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0357-8 · Cited by 144
Self-citationNitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation
Ridnour, L. A., Barasch, K. M., Windhausen, A. N., Dorsey, T. H., Lizardo, M. M., Yfantis, H. G., Lee, D. H., Switzer, C. H., Cheng, R. Y. S., Heinecke, J. L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044081 · Cited by 71
“In support of these observations, TIMP-1 was found to reduce tumor cell sensitivity to chemotherapeutic drug treatment of cells grown in culture [16].”
BackgroundHernández‐Guillamon, M., Delgado, P., Ortega, L., Pares, M., Rosell, A., García‐Bonilla, L., Fernández‐Cadenas, I., Borrell‐Pagès, M., Boada, M., & Montaner, J. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22034 · Cited by 39
Metadata
- Authors
- Davidsen, M. L., Würtz, S., Rømer, M. U., Sørensen, N. M., Johansen, S. K., Christensen, I. J., Larsen, J. K., Offenberg, H., Brünner, N., & Lademann, U.
- Venue
- British Journal of Cancer
- Published
- 2006-10
- Volume
- 95
- Issue
- 8
- Pages
- 1114-1120
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1991803238
- Cited by
- 68
- References
- 2
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.